Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Biosciences Raises $25M in Series C Funding Round

Premium

Predictive Biosciences this week announced the completion of a $25 million Series C funding round.

The proceeds will be used to complete multi-center trials for Predictive's CertNDx bladder cancer diagnostic and for the commercial launch of the test through its CLIA certified laboratories, the company said in a statement.

As opposed to most cancer biomarker tests, CertNDx focuses on negative predictive value – the probability that a patient who has tested negative for cancer is actually free of the disease. This is of particular utility for bladder cancer given that post-treatment, patients typically must receive regular cystoscopies for the rest of their lives in order to test for recurrence.

The CertNDx test combines the use of urinary matrix metalloproteinases – a family of zinc-dependent endopeptidases associated with certain cancers – as protein biomarkers with a real-time PCR assay for detecting mutations in fibroblast growth factor receptor 3 in urine samples. MMPs are associated with high-grade invasive tumors, while FGFR3 mutations are associated with low-stage, non-invasive tumors. Combining the two tests improves the negative predictive value of the CertNDx diagnostic from 94 percent with the MMP-based assay alone to 97 percent, the company concluded in a poster presented in December 2009 at the 10th Annual Meeting of the Society for Urologic Oncology.

Investors in the round included the company's previous investors Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, and New Enterprise Associates, along with new investor ProQuest Investments.

In addition to funding development and commercialization of the CertNDx test, the money will be used to fund the expansion of OncoDiagnostic Laboratory, the anatomic pathology lab services firm the company acquired in January.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.